Remdesivir is active <i>in vitro</i> against tick-borne encephalitis virus and selects for resistance mutations in the viral RNA-dependent RNA polymerase
RDV exhibits potent <i>in vitro</i> antiviral activity against TBEV via specific targeting of the viral RdRp as confirmed by the emergence of resistance-associated double NS5 substitutions <i>in vitro</i> in the presence of RDV. While the potential <i>in vivo</i> implications of the observed RDV resistance remain to be determined, these <i>in vitro</i> data support further assessment of RDV for the treatment of TBEV infection.
Authors
- Marianela Patzi Churqui (ORCID: https://orcid.org/0000-0002-1853-5287)
- Tomáš Cihlář (ORCID: https://orcid.org/0000-0001-6840-0885)
- Edward Trybala (ORCID: https://orcid.org/0000-0003-2384-2123)
- Martin Lagging (ORCID: https://orcid.org/0000-0002-7995-3626)
- Tomas Bergström (ORCID: https://orcid.org/0000-0002-9257-6757)
- Ambjörn Kärmander (ORCID: https://orcid.org/0000-0002-5842-9980)
- John P. Bilello (ORCID: https://orcid.org/0000-0003-4327-1727)
- Joanna Said (ORCID: https://orcid.org/0000-0002-4082-7374)
- Kristina Nystrôm (ORCID: https://orcid.org/0000-0002-1692-8677)
- Anette Roth
Institutions
- Sahlgrenska University Hospital (SE)
- Region Västra Götaland (SE)
- Gilead Sciences (United States) (US)
- University of Gothenburg (SE)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1080/23744235.2025.2468510
- Citations
- 3
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Medicinska Forskningsrådet